MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, S.-H.
Right arrow Articles by Lee, Y.-S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, S.-H.
Right arrow Articles by Lee, Y.-S.

Vol. 57, Issue 5, 883-889, May 2000

Importance of Valine at Position 152 for the Substrate Transport and 2beta -Carbomethoxy-3beta -(4-fluorophenyl)tropane Binding of Dopamine Transporter

Sang-Hun Lee, Mi-yoon Chang, Ki-Hwan Lee, Byung Sup Park, Young-Seek Lee, Hemin R. Chin, and Yong-Sung Lee

Department of Biochemistry, College of Medicine (S.-H.L., M.-Y.C., K.-H.L., B.S.P., Yong-Sung L.); and the Mental Health Research Institute (S.-H.L., M.-Y.C., K.-H.L., B.Y.P., Young-Seek L., Yong-Sung L.), Hanyang University, Seoul, Korea; and the Division of Basic and Clinical Neuroscience Research, National Institute of Mental Health, Bethesda, Maryland (H.R.C.)

Human and bovine dopamine transporters (DAT) demonstrate discrete functional differences in dopamine (DA), 1-methyl-4-phenylpyridium (MPP+) transport, and cocaine analog binding. In a previous study, the functional analyses on the chimeras of human and bovine DAT have revealed that the region from residues 133 through 186 (encompassing the third transmembrane domain) is responsible for the substrate transport and cocaine analog binding. The present study has been carried out to determine the specific amino acid(s) conferring DAT functions by interchanging the amino acid residues in the corresponding region between human and bovine DAT. As described previously, the DA, MPP+ transport, and 2beta -carbomethoxy-3beta -(4-fluorophenyl)tropane (CFT) binding almost disappeared in chimera hb3 in which the region from residues 133 through 186 of bovine DAT was substituted into human DAT. Replacement of isoleucine, residue 152 of chimera hb3 (bovine DAT sequence), with valine, the human DAT residue at the identical position, remarkably restored the substrate transport and CFT binding to 76% to 98% of the human DAT values. Similarly, substitution of isoleucine for valine at position 152 in the human DAT reduced the substrate transport and CFT binding by 57% to 97%. Among other amino acids tested at position 152 of the chimera hb3, only alanine resulted in small but significant increases in the DAT functions ranging from 16 to 34%. Thus, valine at position 152 plays a crucial role for molecular mechanisms underlying the interactions of DA, MPP+, and CFT with human DAT.

Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Cell Sci.Home page
C.-H. Park, J. S. Kang, J.-S. Kim, S. Chung, J.-Y. Koh, E.-H. Yoon, A. Y. Jo, M.-Y. Chang, H.-C. Koh, S. Hwang, et al.
Differential actions of the proneural genes encoding Mash1 and neurogenins in Nurr1-induced dopamine neuron differentiation
J. Cell Sci., June 1, 2006; 119(11): 2310 - 2320.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. K. Henry, J. R. Field, E. M. Adkins, M. L. Parnas, R. A. Vaughan, M.-F. Zou, A. H. Newman, and R. D. Blakely
Tyr-95 and Ile-172 in Transmembrane Segments 1 and 3 of Human Serotonin Transporters Interact to Establish High Affinity Recognition of Antidepressants
J. Biol. Chem., January 27, 2006; 281(4): 2012 - 2023.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
J. D. Gaffaney and R. A. Vaughan
Uptake Inhibitors but not Substrates Induce Protease Resistance in Extracellular Loop Two of the Dopamine Transporter
Mol. Pharmacol., March 1, 2004; 65(3): 692 - 701.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. W. Ravna, I. Sylte, and S. G. Dahl
Molecular Mechanism of Citalopram and Cocaine Interactions with Neurotransmitter Transporters
J. Pharmacol. Exp. Ther., October 1, 2003; 307(1): 34 - 41.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. K. Henry, E. M. Adkins, Q. Han, and R. D. Blakely
Serotonin and Cocaine-sensitive Inactivation of Human Serotonin Transporters by Methanethiosulfonates Targeted to Transmembrane Domain I
J. Biol. Chem., September 26, 2003; 278(39): 37052 - 37063.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
X. Wu and H. H. Gu
Cocaine Affinity Decreased by Mutations of Aromatic Residue Phenylalanine 105 in the Transmembrane Domain 2 of Dopamine Transporter
Mol. Pharmacol., March 1, 2003; 63(3): 653 - 658.
[Abstract] [Full Text] [PDF]

Home page
 Biophys. JHome page
M. Li and H. A. Lester
Early Fluorescence Signals Detect Transitions at Mammalian Serotonin Transporters
Biophys. J., July 1, 2002; 83(1): 206 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
Z. Lin and G. R. Uhl
Dopamine Transporter Mutants with Cocaine Resistance and Normal Dopamine Uptake Provide Targets for Cocaine Antagonism
Mol. Pharmacol., April 1, 2002; 61(4): 885 - 891.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
R. A. Vaughan, J. D. Gaffaney, J. R. Lever, M. E. A. Reith, and A. K. Dutta
Dual Incorporation of Photoaffinity Ligands on Dopamine Transporters Implicates Proximity of Labeled Domains
Mol. Pharmacol., April 16, 2001; 59(5): 1157 - 1164.
[Abstract] [Full Text]

Home page
 Mol. Pharmacol.Home page
E. M. Adkins, E. L. Barker, and R. D. Blakely
Interactions of Tryptamine Derivatives with Serotonin Transporter Species Variants Implicate Transmembrane Domain I in Substrate Recognition
Mol. Pharmacol., March 1, 2001; 59(3): 514 - 523.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics